Omecamtiv Mecarbil

About Cytokinetics

Founded in 1998 and headquartered in South San Francisco, Cytokinetics has established itself as a leader in muscle-directed therapeutics with over 25 years of experience in muscle biology. The company went public in 2004 and has conducted more than 100 clinical trials with tens of thousands of patients. With their first FDA-approved medicine MYQORZO launched in 2025 and multiple Phase 3 programs advancing, Cytokinetics is transitioning from a development-stage company to a commercial-stage specialty biopharmaceutical company focused on improving outcomes for patients with debilitating muscle dysfunction diseases.

Therapeutic Areas